

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA PIONEER PHARMA HOLDINGS LIMITED

中国先锋医药控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 01345)

VOLUNTARY ANNOUNCEMENT AND BUSINESS UPDATE IN RELATION TO THE APPROVAL OF RE-REGISTRATION OF UROFOLLITROPIN FOR INJECTION WITH IBSA

China Pioneer Pharma Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that, Urofollitropin for injection (the “**Product**”, a gonadotropin drug for treating polycystic ovary syndrome, female infertility, male infertility, and application to in vitro fertilization or other auxiliary pregnancy technologies), a product of which the Group acts as the agent, has been granted the re-registration approval from the National Medical Products Administration of the People’s Republic of China on 14 January 2020.

On 14 October 2019, the Company entered into an exclusive agency agreement (the “**Agreement**”) with a wholly-owned subsidiary of IBSA Institut Biochimique S.A. (“**IBSA**”) in respect of the Product. Pursuant to the Agreement, the Group, through the wholly-owned subsidiary of the Company, obtained the right to be the exclusive agent of the Product in China (excluding the Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan), and will take charge of its relevant administrative work, including importation, storage, logistics, product flow and cash collection, etc. The term of the Agreement is ten years.

By Order of the Board
China Pioneer Pharma Holdings Limited
LI Xinzhou
Chairman

Hong Kong, 20 January 2020

As at the date of this announcement, the directors of the Company are Mr. LI Xinzhou, Mr. LUO Chunyi and Mr. LUK Chi Shing as executive directors, Mr. WU Mijia and Mr. HUI Lap Keung as non-executive directors and Mr. ZHANG Hong, Mr. YAN Guoxiang and Mr. WONG Chi Hung, Stanley as independent non-executive directors.